Immix Biopharma, Inc. (IMMX)
- Previous Close
2.1800 - Open
2.1500 - Bid 2.1200 x 100
- Ask 2.2200 x 100
- Day's Range
2.1300 - 2.2100 - 52 Week Range
1.4000 - 7.7500 - Volume
79,427 - Avg. Volume
182,388 - Market Cap (intraday)
57.055M - Beta (5Y Monthly) 0.24
- PE Ratio (TTM)
-- - EPS (TTM)
-0.8900 - Earnings Date --
- Forward Dividend & Yield --
- Ex-Dividend Date --
- 1y Target Est
14.00
Immix Biopharma, Inc., a clinical-stage biopharmaceutical company, engages in developing tissue-specific therapeutics in oncology and immune-dysregulated diseases in the United States and Australia. The company is developing IMX-110 that is in Phase 1b/2a clinical trials for the treatment of soft tissue sarcoma and colorectal cancer; and NXC-201 for relapsed/refractory multiple myeloma. It has a clinical collaboration and supply agreement with BeiGene Ltd. for a combination Phase 1b clinical trial in solid tumors of IMX-110 and anti-PD-1 Tislelizumab. Immix Biopharma, Inc., was incorporated in 2012 and is headquartered in Los Angeles, California.
www.immixbio.comRecent News: IMMX
Performance Overview: IMMX
Trailing total returns as of 5/13/2024, which may include dividends or other distributions. Benchmark is .
YTD Return
1-Year Return
3-Year Return
5-Year Return
Compare To: IMMX
Select to analyze similar companies using key performance metrics; select up to 4 stocks.
Statistics: IMMX
Valuation Measures
Market Cap
57.05M
Enterprise Value
28.83M
Trailing P/E
--
Forward P/E
--
PEG Ratio (5yr expected)
--
Price/Sales (ttm)
--
Price/Book (mrq)
2.04
Enterprise Value/Revenue
--
Enterprise Value/EBITDA
--
Financial Highlights
Profitability and Income Statement
Profit Margin
0.00%
Return on Assets (ttm)
-57.92%
Return on Equity (ttm)
-106.23%
Revenue (ttm)
--
Net Income Avi to Common (ttm)
-15.43M
Diluted EPS (ttm)
-0.8900
Balance Sheet and Cash Flow
Total Cash (mrq)
17.51M
Total Debt/Equity (mrq)
--
Levered Free Cash Flow (ttm)
-5.94M
Research Analysis: IMMX
Company Insights: IMMX
IMMX does not have Company Insights